Renal Transporter-Mediated Drug-Biomarker Interactions of the Endogenous Substrates Creatinine and N-1-Methylnicotinamide: A PBPK Modeling Approach

Tuerk D, Müller F, Fromm M, Selzer D, Dallmann R, Lehr T (2022)

Publication Type: Journal article

Publication year: 2022

Journal

Clinical Pharmacology & Therapeutics American Society for Clinical Pharmacology and Therapeutics

DOI: 10.1002/cpt.2636

Abstract

Endogenous biomarkers for transporter-mediated drug-drug interaction (DDI) predictions represent a promising approach to facilitate and improve conventional DDI investigations in clinical studies. This approach requires high sensitivity and specificity of biomarkers for the targets of interest (e.g., transport proteins), as well as rigorous characterization of their kinetics, which can be accomplished utilizing physiologically-based pharmacokinetic (PBPK) modeling. Therefore, the objective of this study was to develop PBPK models of the endogenous organic cation transporter (OCT)2 and multidrug and toxin extrusion protein (MATE)1 substrates creatinine and N-1-methylnicotinamide (NMN). Additionally, this study aimed to predict kinetic changes of the biomarkers during administration of the OCT2 and MATE1 perpetrator drugs trimethoprim, pyrimethamine, and cimetidine. Whole-body PBPK models of creatinine and NMN were developed utilizing studies investigating creatinine or NMN exogenous administration and endogenous synthesis. The newly developed models accurately describe and predict observed plasma concentration-time profiles and urinary excretion of both biomarkers. Subsequently, models were coupled to the previously built and evaluated perpetrator models of trimethoprim, pyrimethamine, and cimetidine for interaction predictions. Increased creatinine plasma concentrations and decreased urinary excretion during the drug-biomarker interactions with trimethoprim, pyrimethamine, and cimetidine were well-described. An additional inhibition of NMN synthesis by trimethoprim and pyrimethamine was hypothesized, improving NMN plasma and urine interaction predictions. To summarize, whole-body PBPK models of creatinine and NMN were built and evaluated to better assess creatinine and NMN kinetics while uncovering knowledge gaps for future research. The models can support investigations of renal transporter-mediated DDIs during drug development.

Authors with CRIS profile

Fabian Müller Lehrstuhl für Klinische Pharmakologie und Klinische Toxikologie Martin Fromm Lehrstuhl für Klinische Pharmakologie und Klinische Toxikologie

Involved external institutions

Universität des Saarlandes (UdS) DE Germany (DE) University of Warwick GB United Kingdom (GB)

How to cite

APA:

Tuerk, D., Müller, F., Fromm, M., Selzer, D., Dallmann, R., & Lehr, T. (2022). Renal Transporter-Mediated Drug-Biomarker Interactions of the Endogenous Substrates Creatinine and N-1-Methylnicotinamide: A PBPK Modeling Approach. Clinical Pharmacology & Therapeutics. https://dx.doi.org/10.1002/cpt.2636

MLA:

Tuerk, Denise, et al. "Renal Transporter-Mediated Drug-Biomarker Interactions of the Endogenous Substrates Creatinine and N-1-Methylnicotinamide: A PBPK Modeling Approach." Clinical Pharmacology & Therapeutics (2022).

BibTeX: Download